Early Stage Investing is Name of Game for Versant
This article was originally published in Start Up
Versant Ventures wrapped up $500 million for a new venture fund, an achievement based chiefly on its prowess as an early stage investor.
You may also be interested in...
Glaukos has emerged as the leader in microinvasive glaucoma surgery, a new treatment for the multibillion-dollar market. CEO Tom Burns lays out his vision for his company and for the future of MIGS.
The merger of Pfizer and Allergan might raise broader questions about the fairness – or long-term viability – of the corporate tax code in the US. But it also has generated some angst over Allergan’s future as a stalwart in ophthalmology.
New Enterprise Associates surprised some by locking down $3.1 billion in new capital during a tight fundraising climate. General partner David Mott and partner Justin Klein share the firm’s investment approach.